Study Links Osteoporosis Drugs to Reduced Alzheimer's Risk in Older Adults
A large observational study conducted in Hong Kong has revealed that the use of nitrogen-containing bisphosphonates (NBPs), medications commonly prescribed for osteoporosis, is associated with a 16% lower risk of developing Alzheimer’s disease and other types of dementia among older adults. The study involved 121,492 participants aged 60 and older, all of whom had recently been diagnosed with osteoporosis or had experienced a serious fracture. Notably, none of the participants had previously taken osteoporosis medications.
The findings indicate that those using NBPs had a 24% lower risk of developing dementia compared to individuals taking other types of osteoporosis medications. Bisphosphonates, including alendronate, ibandronate, risedronate, and zoledronate, are designed to slow bone loss and reduce fracture risk, particularly in older adults who are more susceptible to osteoporosis.
Ching-Lung Cheung, an associate professor in the Department of Pharmacology and Pharmacy at the University of Hong Kong, emphasized the emerging evidence of a connection between bone health and brain health, often referred to as the bone-brain axis. Previous studies have indicated that individuals with low bone mass or osteoporosis may have a higher likelihood of developing dementia later in life, underscoring the importance of maintaining good bone health.
Despite these promising findings, Cheung cautioned that the study's observational design does not establish a causal relationship between bisphosphonate use and reduced dementia risk. He noted that further clinical trials are necessary to confirm these results. Additionally, the study's generalizability is limited, as it primarily involved a Chinese population, raising questions about whether these findings can be applied to other demographics.
The researchers also acknowledged several limitations, including the lack of baseline cognitive testing, which may have affected the results. Patients with existing cognitive impairment might have been less likely to receive osteoporosis treatment, potentially skewing the findings. Furthermore, the study did not account for the severity of osteoporosis or fractures among participants, nor did it consider the use of over-the-counter supplements such as calcium and vitamin D.
External factors, including education level, social isolation, air pollution, and vision loss, could also influence dementia risk, complicating the interpretation of the results. While the study suggests a link between NBP use and lower rates of Alzheimer's and related dementias, the authors advise against prescribing bisphosphonates solely for dementia prevention until further evidence is available.
Looking ahead, Cheung and his team call for additional research to explore the potential role of gender in the observed risk reduction and to confirm their findings across broader populations. If future studies validate these results, they could have significant implications for dementia management and treatment strategies.




